CP-456773 钠盐 - CAS:256373-96-3 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	CP-456773 钠盐促销
英文名称:	CP-456773 sodiu salt
别名:	N-[[(1,2,3,5,6,7-六氢-S-引达省-4-基)氨基]羰基]-4-(1-羟基-1-甲基乙基)-2-呋喃磺酰胺单钠盐;N-[[(1,2,3,5,6,7-六氢-s-引达省-4-基)氨基]羰基]-4-(1-羟基-1-甲基乙基)-2-呋喃磺酰胺单钠盐 CP45677;CRID3;Cytoine release inhibitory drug 3；sodiu ((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbaoyl)((4-(2-hydroxypropan-2-yl)furan-2-yl)sulfonyl)aide；MCC950 Na
CAS No:	256373-96-3	分子式:	C₂₀H₂₃N₂NaO₅S	分子量:	426.46
CAS No:	256373-96-3
分子式:	C₂₀H₂₃N₂NaO₅S
分子量:	426.46

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF) 点击下载技术规格说明书(PDF)

C10577 CP-456773 钠盐 ≥98% (普西唐-psaitong)

相关产品

包装规格：

5mg 25mg 100mg in glass bottle

溶解性：

溶于水(20mg/mL )

产品描述：

基本信息

产品编号：	C10577
产品名称：	CP-456773 sodiu salt
CAS:	256373-96-3	储存条件	粉末	-20℃	四年

分子式：	C20H23N2NaO5S		溶于液体	-80℃	两年
分子量	426.46			-20℃	一个月
化学名：	Sodium((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((4-(2-hydroxypropan-2-yl)furan-2-yl)sulfonyl)amide
Solubility (25°C)：
体外:	DMSO	Insoluble
	Ethanol	85mg/mL(199.31mM)
	Water	85mg/mL(199.31mM)
体内(现配现用):	1.请依序添加每种溶剂：PBS Solubility:6.25mg/mL(14.66mM);Clear solution; Need ultrasonic 2.请依序添加每种溶剂：5% DMSO→95% PBS Solubility:≥5mg/mL(11.72mM);Clear solution 3请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline，Solubility:≥2.08mg/mL(4.88mM);Clear solution
	此⽅案可获得≥2.08mg/mL(4.88mM，饱和度未知)的澄清溶液。以1mL⼯作液为例，取100μL20.8mg/mL的澄清DMSO储备液加到400μLPEG300中，混合均匀；向上述体系中加⼊50μLTween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。
	4请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility:≥2.08mg/mL(4.88mM);Clear solution
	此⽅案可获得≥2.08mg/mL(4.88mM，饱和度未知)的澄清溶液。以1mL⼯作液为例，取100μL20.8mg/mL的澄清DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶液中，混合均匀。
	5.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility:≥2.08mg/mL(4.88mM);Clear solution
	此⽅案可获得 ≥ 2.08mg/mL (4.88mM，饱和度未知) 的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以 1 mL ⼯作液为例，取 100 μL 20.8mg/mL 的澄清 DMSO 储备液加到 900 μL ⽟⽶油中，混合均匀。
	6.请依序添加每种溶剂：2％DMSO→98％PBS Solubility:≥2mg/mL(4.69mM);Clear solution
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	2.3449mL	11.7244mL	23.4489mL
5mM	0.4690mL	2.3449mL	4.6898mL
10mM	0.2345mL	1.1724mL	2.3449mL
50mM	0.0469mL	0.2345mL	0.4690mL

生物活性

产品描述	一种有效的选择性的NLRP3抑制剂。
靶点	NLRP3 (in BMDM (bone marrow derived macrophages)) 7.5nM	NLRP3 (in HMDM) 8.1nM
体外研究	MCC950在骨髓来源的巨噬细胞和人类单核细胞衍生的巨噬细胞中，抑制经典和非经典NLRP3激活，IC50分别为7.5和8.1nM。MCC950特异性抑制NLRP3的激活，不抑制AIM2, NLRC4或NLRP1这些炎症小体。
体内研究	MCC950减少白介素-1β(IL-1β)的产生、减轻实验性自身免疫性脑脊髓炎的严重性。在自身炎症性疾病Cryopyrin蛋白相关周期性综合征的小鼠模型中，MCC950能够挽救其新生时期的死亡。在间接体外实验中，在来源于韦二氏综合征患者的样品具有活性。

推荐实验方法(仅供参考)

Cell Assay

BMDM are seeded at 5×10⁵ /mL or 1×10⁶ /mL, HMDM at 5×10⁵ /mL and PBMC at 2×10⁶ /mL or 5×10⁶/mL in 96 well plates. Thefollowing day the overnight medium is replaced and cells are stimulated with 10ng/mL LPS from Escherichia coli serotype EH100 (ra) TLRgrad for 3 h. Medium is removed and replaced with serum free medium (SFM) containing DMSO (1:1,000), MCC950 (0.001-10µM), Parthenolide (10µM) or Bayer cysteinyl leukotriene receptor antagonist 1-(5-carboxy-2{3-[4-(3-cyclohexylpropoxy)phenyl]propoxy}benzoyl)piperidine-4-carboxylic acid (40µM) for 30 min. Cells are then stimulated with inflammasome activators: 5mM adenosine 5’-triphosphate disodium salt hydrate (ATP) (1 h), 1µg/mL Poly(deoxyadenylicthymidylic) acid sodium salt (Poly dA:dT) transfected with Lipofectamine 200 (3-4 h), 200µg/mL MSU (overnight) and 10µM nigericin (1 h) or S. typhimurium UK-1 strain. Cells are also stimulated with 25µg/mL Polyadenylic-polyuridylic acid (4 h). For non-canonical inflammasome activation cells are primed with 100ng/mL Pam3CSK4 for 4 h, medium is removed and replaced with SFM containing DMSO or MCC950 and 2µg/mL LPS is transfected using 0.25% FuGENE for 16 h. Supernatants are removed and analysed using ELISA kits. LDH release is measured using the CytoTox96 non-radioactive cytotoxicity assay

Animal Administration

Mice

C57BL/6 mice are immunized subcutaneously with 150µg of MOG peptide 35-55 emulsified in CFA containing 4mg/mL (0.4.mg/mouse) of heat-killed MTB. Mice are injected i.p. with 500ng pertussis toxin (PT: kaketsuken) on days 0 and 2. MCC950 is administered i.p. to mice (10mg/kg) at induction of the disease, day 0, 1 and 2 and every 2 days thereafter. Control mice are administered vehicle (PBS) at the same time points. Mice are observed for clinical signs of disease daily (unblinded). Disease severity is scored as follows: no clinical signs, 0; limp tail, 1; ataxic gait, 2; hind limb weakness, 3; hind limb paralysis, 4; and tetra paralysis, 5.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

点击下载高效液相/气相图谱(PDF)

点击下载核磁/氢谱图谱(PDF)

搜索质检报告(COA)

参考文献 & 客户发表文献